Renal function impairment predicts mortality in patients with chronic heart failure treated with resynchronization therapy

Gronda, Edoardo; Genovese, Stefano; Padeletti, Luigi; Cacciatore, Francesco; Vitale, Dino Franco; Bragato, Renato; Innocenti, Lisa; Schiano, Concetta; Sommese, Linda; Pascale, Maria Rosaria; Genovese, Luca; Abete, Pasquale; Donatelli, Francesco; Napoli, Claudio

doi:10.5603/cj.a2015.0019

Cited by 14 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies have shown that chronic kidney disease (CKD) is associated with high cardiovascular mortality as a result of accelerated atherosclerosis. An increased predisposition to atherosclerosis is largely driven by chronic inflammation, oxidative stress, and dyslipidaemia, which are usually associated with CKD [1,2,3]. The dyslipidemia of CKD patients is classically characterized by hypertriglyceridemia and a low concentration of high-density lipoprotein cholesterol (HDL-C) associated with normal or slightly reduced low-density lipoprotein cholesterol (LDL-C) levels [4,5].…”

Section: Introductionmentioning

confidence: 99%

Plasma Levels of Preβ1-HDL Are Significantly Elevated in Non-Dialyzed Patients with Advanced Stages of Chronic Kidney Disease

Kuchta

Ćwiklińska

Czaplińska

et al. 2019

IJMS

View full text Add to dashboard Cite

In chronic kidney disease (CKD), the level of high-density lipoprotein (HDL) decreases markedly, but there is no strong inverse relationship between HDL-cholesterol (HDL-C) and cardiovascular diseases. This indicates that not only the HDL-C level, but also the other quantitative changes in the HDL particles can influence the protective functionality of these particles, and can play a key role in the increase of cardiovascular risk in CKD patients. The aim of the present study was the evaluation of the parameters that may give additional information about the HDL particles in the course of progressing CKD. For this purpose, we analyzed the concentrations of HDL containing apolipoprotein A-I without apolipoprotein A-II (LpA-I), preβ1-HDL, and myeloperoxidase (MPO), and the activity of paraoxonase-1 (PON-1) in 68 patients at various stages of CKD. The concentration of HDL cholesterol, MPO, PON-1, and lecithin-cholesterol acyltransferase (LCAT) activity were similar in all of the analyzed stages of CKD. We did not notice significant changes in the LpA-I concentrations in the following stages of CKD (3a CKD stage: 57 ± 19; 3b CKD stage: 54 ± 15; 4 CKD stage: 52 ± 14; p = 0.49). We found, however, that the preβ1-HDL concentration and preβ1-HDL/LpA-I ratio increased along with the progress of CKD, and were inversely correlated with the estimated glomerular filtration rate (eGFR), even after adjusting for age, gender, triacylglycerols (TAG), HDL cholesterol, and statin therapy (β = −0.41, p < 0.001; β = −0.33, p = 0.001, respectively). Our results support the earlier hypothesis that kidney disease leads to the modification of HDL particles, and show that the preβ1-HDL concentration is significantly elevated in non-dialyzed patients with advanced stages of CKD.

show abstract

Section: Introductionmentioning

confidence: 99%

Plasma Levels of Preβ1-HDL Are Significantly Elevated in Non-Dialyzed Patients with Advanced Stages of Chronic Kidney Disease

Kuchta

Ćwiklińska

Czaplińska

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Acute decompensated HF often causes acute pre-renal kidney failure due to decreased blood flow through the kidneys. Chronic HF also often co-exists with chronic kidney failure, which is associated with increased activity of the renin-angiotensin-aldosterone system, oxidative stress, inflammation, and increased activity of the sympathetic nervous system [15]. These are the cornerstones of cardiorenal syndrome patho- Table 2.…”

Section: Our Analysis Of 638 Decompensated Hf Patients Demonstratesmentioning

confidence: 99%

Basic laboratory parameters as predictors of in-hospital death in patients with acute decompensated heart failure: data from a large single-centre cohort

Ostrowska

Ostrowski

Łuczak³

et al. 2017

Kardiol Pol

View full text Add to dashboard Cite

A b s t r a c tBackground: Heart failure (HF) is a growing cause of hospitalisation worldwide, and despite significant progress in its treatment it is still associated with high mortality. Aim:The aim of this study was to find factors predicting in-hospital death in acute decompensated HF by analysis of basic laboratory data and echocardiography, routinely collected on admission to the hospital. Methods:To this single-centre retrospective study we involved 638 consecutive patients hospitalised in the years 2007-2008 due to acute decompensated HF. To the initial univariate analysis we included the results of echocardiography and 36 basic laboratory tests performed at hospital admission. Parameters significantly associated with in-hospital death in univariate analysis were taken to multivariate regression analysis. Results:In-hospital death occurred in 119 cases (median age 75 years; 40.3% females). The multivariate analysis revealed significant association between in-hospital death and: higher leukocyte count (death [D]: 13.5 vs. survival [S]: 8

show abstract

“…There are very few studies investigating the role of CRT in the improvement of renal function in patients with HF and chronic renal dysfunction [14,36]. An observational study revealed that patients with baseline CKD showed an improvement in eGFR (mean change: 4.24±14.2 mL/min/1.73 m 2 ), and patients without baseline CKD showed a decrease in GFR (mean change eGFR: 3.01±20.9 mL/min/1.73 m 2 ) [14]. Recently, a study including 260 patients demonstrated that the severity of baseline CKD was significantly associated with an increased risk of death, transplantation, or left ventricular assist device [37].…”

Section: Discussionmentioning

confidence: 99%

“…Subsequently, 178 studies were excluded at the title/abstract level, and 31 studies were excluded at the full text level, according to the criteria mentioned above. As a result, 16 studies [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] satisfied our inclusion criteria and were included in our analysis.…”

Section: Studies and Patientsmentioning

confidence: 99%

Impact of baseline renal function on all‐cause mortality in patients who underwent cardiac resynchronization therapy: A systematic review and meta‐analysis

Bazoukis

Letsas

Korantzopoulos

et al. 2017

Journal of Arrhythmia

View full text Add to dashboard Cite

BackgroundCardiac resynchronization therapy (CRT) improves both morbidity and mortality in selected patients with heart failure and increased QRS duration. However, chronic kidney disease (CKD) may have an adverse effect on patient outcome. The aim of this systematic review was to analyze the existing data regarding the impact of baseline renal function on all-cause mortality in patients who underwent CRT.MethodsMedline database was searched systematically, and studies evaluating the effect of baseline renal function on all-cause mortality in patients who underwent CRT were retrieved. We performed three separate analyses according to the comparison groups included in each study. Data were analyzed using Review Manager software (RevMan version 5.3; Oxford, UK).ResultsWe included 16 relevant studies in our analysis. Specifically, 13 studies showed a statistically significant higher risk of all-cause mortality in patients with impaired baseline renal function who underwent CRT. The remaining three studies did not show a statistically significant result. The quantitative synthesis of five studies showed a 19% decrease in all-cause mortality per 10-unit increment in estimated glomerular filtration rate (eGFR) [HR: 0.81, 95% CI (0.73–0.90), p<0.01, 86% I2]. Additionally, we demonstrated that patients with an eGFR<60 mL/min/1.73 m2 had an all-cause mortality rate of 66% [HR: 1.66, 95% CI (1.37–2.02), p<0.01, 0% I2], which was higher than in those with an eGFR≥60 mL/min/1.73 m2.ConclusionBaseline renal dysfunction has an adverse effect on-all cause mortality in patients who underwent CRT.

show abstract

Renal function impairment predicts mortality in patients with chronic heart failure treated with resynchronization therapy

Abstract: Background: The use of cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) for advanced heart failure (HF) is increasing. Renal dysfunction is a common condition in (Cardiol J 2015; 22, 4: 459-466)

Cited by 14 publications

References 29 publications

Plasma Levels of Preβ1-HDL Are Significantly Elevated in Non-Dialyzed Patients with Advanced Stages of Chronic Kidney Disease

Plasma Levels of Preβ1-HDL Are Significantly Elevated in Non-Dialyzed Patients with Advanced Stages of Chronic Kidney Disease

Basic laboratory parameters as predictors of in-hospital death in patients with acute decompensated heart failure: data from a large single-centre cohort

Impact of baseline renal function on all‐cause mortality in patients who underwent cardiac resynchronization therapy: A systematic review and meta‐analysis

Contact Info

Product

Resources

About